Filing Flows › Caribou Biosciences (CRBU) › Q1 2026
Caribou Biosciences (CRBU) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Caribou Biosciences (CRBU) reported revenue of $2.4M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -39% from the quarter before.
Caribou Biosciences, Q1 2026: revenue $2.4M (+2% year over year), net loss $25.1M, operating cash flow −$27.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | -39% | +2% |
| Operating profit | −$26.3M | — | — |
| Net earnings | −$25.1M | — | — |
| Operating cash flow | −$27.0M | — | — |
What changed
Revenue was $2.4M in Q1 2026, up 2% year over year and down 39% from the previous quarter.
Operating costs exceeded revenue by $26.3M, an operating margin of -1096.4%. Total costs fell 37% while revenue rose 2%. The quarter ended with a net loss of $25.1M, narrower than the previous quarter's $26.5M loss.
Operating cash flow was −$27.0M. Non-cash charges added back $649K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $4.9M. Capital expenditures of $72K exceeded it, leaving free cash flow of −$27.1M.
Questions
What was Caribou Biosciences' revenue in the first quarter 2026?
Caribou Biosciences (CRBU) reported revenue of $2.4M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -39% from the quarter before.